Tenax Therapeutics
TENX
10 hedge funds and large institutions have $1.56M invested in Tenax Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0.01% less ownership
Funds ownership: 0.02% → 0.01% (-0.01%)
23% less capital invested
Capital invested by funds: $2.04M → $1.56M (-$471K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$179K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$14.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$39K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7.26K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$4.84K |
| 4 |
Bank of New York Mellon
New York
|
-$2.42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $827K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $496K | +$179K | +74 | +49% |
|
|
FWP
3
FAS Wealth Partners
Leawood,
Kansas
| $81K | – | – | – |
|
|
4
Bank of New York Mellon
New York
| $49K | -$2.42K | -1 | -4% |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $45K | +$9.68K | +4 | +24% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $30K | +$31.5K | +13 | New |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $17K | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| $14K | +$14.5K | +6 | New |
|
|
AG
9
Advisor Group
Phoenix,
Arizona
| $4K | -$4.84K | -2 | -50% |
|
|
10
UBS Group
Zurich,
Switzerland
| $2K | -$7.26K | -3 | -75% |
|
|
11
Jane Street
New York
| – | -$39K | -12 | Closed |
|
TENX Hedge Fund Activity: Q2 2019 in Review
10 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q2 2019, worth a combined $1.56M — down 23% from $2.04M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TENX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $179K. The largest seller was Jane Street, exiting entirely with an estimated $39K sold.
- 10 institutional investors held Tenax Therapeutics (TENX) as of Q2 2019, up from 9 in Q1 2019.
- Funds reported $1.56M of Tenax Therapeutics stock for Q2 2019, down 23% quarter-over-quarter.
- 2 funds opened new Tenax Therapeutics positions in Q2 2019 and 1 closed out, a net change of +1 holder.
- The largest Tenax Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $179K added.
- The largest Tenax Therapeutics seller in Q2 2019 was Jane Street, an estimated $39K sold.
Based on aggregated 13F filings for Q2 2019.